Annexon Biosciences
Annexon Biosciences is a biopharmaceutical company headquartered in Brisbane, California, specializing in developing therapies for autoimmune, neurodegenerative, and ophthalmic diseases by targeting C1q to inhibit the classical complement pathway.
Company Overview
Annexon Biosciences is headquartered in Brisbane, California and focuses on developing therapies for autoimmune, neurodegenerative, and ophthalmic diseases. They target the C1q protein to inhibit the classical complement pathway. The company is publicly traded on the Nasdaq under the ticker symbol ANNX.
Therapeutic Areas
Annexon Biosciences develops treatments primarily for autoimmune, neurodegenerative, and ophthalmic diseases. Their pipeline includes therapies addressing conditions such as Guillain-Barré syndrome and geographic atrophy. The company's approach targets the C1q protein to inhibit the classical complement pathway, with the objective of treating these serious diseases.
Drug Candidates
The key drug candidates in clinical trials for Annexon Biosciences include ANX005 and ANX007. ANX005 has received Fast Track and Orphan Drug designations from the FDA, reflecting its potential to address unmet medical needs and to treat rare diseases. ANX007 has received the Priority Medicines (PRIME) designation from the European Medicines Agency, signifying its promise in treating conditions with substantial unmet need.
Pipeline and Clinical Trials
Annexon Biosciences' pipeline features various therapies targeting significant diseases. Active development includes ANX005, geared towards treating Guillain-Barré syndrome and ANX007, aimed at geographic atrophy. These drug candidates are currently undergoing clinical trials, highlighting the company's commitment to advancing medical research and therapeutic innovation.